A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

Stopped Sponsor decision to terminate study based on results of parent study GBT2104-131.

Conditions

• Sickle Cell Disease
• Vaso-occlusive Crisis
• Vaso-occlusive Pain Episode in Sickle Cell Disease

Interventions

• DRUG: Inclacumab

Sponsor

Pfizer